REVIVE is an international multi-centre trial to evaluate azithromycin prophylaxis to reduce excess mortality among people with advanced HIV disease and CD4 count of 100 cells/mm3 or less.

Azithromycin, provided for 4 weeks together with antiretroviral therapy, will be compared with matching placebo and given on a background of standard of care for advanced HIV disease, as determined by relevant local guidelines.

Primary outcome:
All-cause mortality at 24 weeks after randomization

Secondary outcomes:
• All-cause mortality at 12 weeks
• Hospitalization at 24 weeks
• Composite of hospitalization and all-cause mortality at 24 weeks

Sub-studies will evaluate additional outcomes of interest including cause of death and carriage of antimicrobial resistant pathogens, as well cost-effectiveness of azithromycin.

For inquiries about the REVIVE study, please don’t hesitate to reach out to the research team at

REVIVE design and countries
Study Type


Study Design

Double blinded, placebo-controlled

NO. of Countries

6 (vanguard); 13 (main trial)

NO. of Sites

20 (vanguard); 150 (main trial)

NO. of Participants


Study Period



Population Health Research Institute

University of Cape Town

Bill & Melinda Gates Foundation

Back To Top